Get the Stockscreener App
1.738
0.87%
0.018
Jasper Therapeutics Inc stock is traded at $1.738, with a volume of 286.39K.
It is up +0.87% in the last 24 hours and down -26.79% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$1.72
Open:
$1.75
24h Volume:
286.39K
Relative Volume:
0.78
Market Cap:
$48.55M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.281
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-5.19%
1M Performance:
-26.79%
6M Performance:
-63.63%
1Y Performance:
-92.37%
1-Day Range:
$1.71
$1.80
1-Week Range:
$1.68
$1.97
52-Week Range:
$1.56
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.735 | 48.13M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.21 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.27 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.32 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.65 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics to Present at Upcoming Investor Conferences - Sahm
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Investor Alert: Deadline in Lawsuit on November 18, 2025 - openPR.com
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Markets Financial Content
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Jasper Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, - GlobeNewswire
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
JSPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Jasper Therapeutics, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Bank of Montreal Can Has $878,000 Stock Position in Jasper Therapeutics, Inc. $JSPR - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
William Blair Has Negative Outlook of JSPR FY2025 Earnings - Defense World
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Th - GuruFocus
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
International Business Times - Markets Financial Content
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025JSPR - MarketScreener
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
JSPR DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR RIGHTS - GlobeNewswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RBC Capital Maintains Jasper Therapeutics (JSPR) Sector Perform Recommendation - Nasdaq
Jasper Therapeutics stock price target lowered to $4 at RBC on BEACON concerns - Investing.com Canada
A look into Jasper Therapeutics Inc (JSPR)’s deeper side - Setenews
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Get in on Rani Therapeutics Holdings Inc’s (RANI) buy-in window today! - setenews.com
RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Jasper Therapeutics Reports Q3 2025 Financial Results - TipRanks
JSPR DEADLINE ALERT: ROSEN, A TOP-RANKED LAW FIRM, - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29) - TipRanks
Jasper Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report | JSPR SEC FilingForm 10-Q - Stock Titan
Jasper Therapeutics Q3 loss smaller than estimates - MarketScreener
[8-K] Jasper Therapeutics, Inc. Reports Material Event | JSPR SEC FilingForm 8-K - Stock Titan
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):